Adverse Event Management

October 06, 2022

Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant.

October 04, 2022

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.

October 03, 2022

Karen Hande, PhD, DNP, ANP-BC, CNE, FAANP, ANEF, discusses increased patient interest in cannabinoids and how oncology nurses can steer pain management conversations to keep patients informed.

September 29, 2022

The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.

September 26, 2022

Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.

September 22, 2022

The FDA has approved eflapegrastim to treat febrile neutropenia. The agent should be administered 24 hours following cytotoxic chemotherapy. It comes with warnings for fatal splenic rupture, acute respiratory distress syndrome, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, and myelodysplastic syndrome.

September 21, 2022

In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.

September 21, 2022

In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.

September 15, 2022

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.

September 14, 2022

Kelly Goodwin, MSN, RN, ANP-BC, discusses the significance of the recent FDA approvals of capmatinib and trastuzumab deruxtecan for patients with non–small cell lung cancer.